Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.52 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.33 |
| ▸ | CA1 | P00915 | 2/20 | 0.33 |
| ▸ | CA2 | P00918 | 2/20 | 0.33 |
| ▸ | FDPS | P14324 | 2/20 | 0.33 |
| ▸ | MAPT | P10636 | 2/20 | 0.33 |
| ▸ | POLB | P06746 | 2/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.33 |
| ▸ | LMNA | P02545 | 1/20 | 0.33 |
| ▸ | HTT | P42858 | 1/20 | 0.33 |
| ▸ | TSHR | P16473 | 2/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.32 |
| ▸ | MGLL | Q99685 | 1/20 | 0.32 |
| ▸ | TP53 | P04637 | 1/20 | 0.31 |
| ▸ | RAB9A | P51151 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL60399 | 1.00 | — | — | |
| SCHEMBL518261 | 1.00 | HSD17B10 (0.52) | HSD17B10SMN1; SMN2ALDH1A1CA1CA2 | |
| SCHEMBL2638 | 1.00 | — | — | |
| SCHEMBL1521924 | 1.00 | — | — | |
| SCHEMBL20055722 | 1.00 | HSD17B10 (0.52) | HSD17B10SMN1; SMN2ALDH1A1CA1CA2 | |
| SCHEMBL10546260 | 0.96 | HSD17B10 (0.50) | HSD17B10SMN1; SMN2ALDH1A1CA1CA2 | |
| SCHEMBL5881106 | 0.96 | HSD17B10 (0.50) | HSD17B10SMN1; SMN2ALDH1A1CA1CA2 | |
| Ammonia Solution, Strong SCHEMBL6053445 | 0.96 | HSD17B10 (0.50) | HSD17B10SMN1; SMN2ALDH1A1CA1CA2 | |
| SCHEMBL16492 | 0.96 | HSD17B10 (0.50) | HSD17B10SMN1; SMN2ALDH1A1CA1CA2 | |
| SCHEMBL18507037 | 0.96 | HSD17B10 (0.48) | HSD17B10SMN1; SMN2TSHRKMT2ARAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120065395-A1 | 2,4 (4,6) PYRIMIDINE DERIVATIVES | FREYNE EDDY JEAN EDGARD (BE) | 2012-03-15 | — | — | US | disclosed |
| CN-101160303-B | 1- (2H) -isoquinolone derivatives | CHUGAI PHARMACEUTICAL CO LTD | 2011-09-28 | — | — | CN | disclosed |
| CN-101160303-A | 1- (2H) -isoquinolone derivatives | CHUGAI PHARMACEUTICAL CO LTD (JP) | 2008-04-09 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120065395-A1 | 2,4 (4,6) PYRIMIDINE DERIVATIVES | NR0B1, NR1H3, NCOA3 | HSD17B10 139/4885SMN1; SMN2 4387/4885ALDH1A1 1457/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.